Antibody combo lowers hospitalizations in high-risk COVID-19 patientsHigh-risk adults with mild to moderate COVID-19 who receive a dose of casirivimab and imdevimab have lower hospitalization rates than those who don't, according to a randomized, controlled trial today in The Lancet's EClinicalMedicine.
The casirivimab and imdevimab combination is under emergency use authorization by the US Food and Drug Administration.Mayo Clinic researchers paired 696 intervention patients with 696 control patients from Arizona, Florida, Minnesota, and Wisconsin from Dec 4, 2020, to Apr 9, 2021.
All were at high risk: 45.5% were 65 or older, and common underlying conditions included high blood pressure (52.4%), body mass index (BMI) of 35 kg/m2 or higher